Two years after Neil Armstrong walked on the Moon, US president Richard Nixon declared a new frontier in American scientific ...

X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in ...

YONGIN, South Korea I March 12, 2025 I GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 ...

Aimed at expanding possibilities for NK‑cell therapies, GCC2005 is an allogeneic cell therapy product manufactured using umbilical cord blood–derived NK cells. Engineered to target the CD5 ...

To enable this innovation, Medigene combined TCR-guided precision targeting with innate NK cell killing. The Company has developed a proprietary universal scaffold that allows its 3S TCRs to function ...

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, ...

Coeptis Inc. (Nasdaq: COEP) has taken a bold step forward in the fight against cancer by securing exclusive worldwide ...

Wexford-based biopharmaceutical company Coeptis Inc. announced the formation of GEAR Therapeutics, a majority-owned ...

2025 年 2 月 10 日，中国科学技术大学生命科学与医学部、免疫应答与免疫治疗全国重点实验室王毅课题组在 Cell 子刊 Molecular Therapy 在线发表了题为“ A BPTF-specific PROTAC degrader enhances NK cell-based cancer immunotherapy ” 的研究论文 肿瘤微环境通过免疫抑制因子失衡 ...

X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in T-cell, B-cell, and natural ...

announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This "first patient dosing" marks a critical milestone in the company's ...